{"url_path":"/sec/arwr/8-k/2026-06-16/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/879407/0000879407-26-000050-index.html","accession_number":"0000879407-26-000050","cik":"0000879407","ticker":"ARWR","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/879407/0000879407-26-000050-index.html","primary_entity_key":"0000879407","primary_entity_name":"ARROWHEAD PHARMACEUTICALS, INC."},"word_count":67,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits.\n\n(d) Exhibits\n\nExhibit No.Description\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nDate: June 16, 2026\n\nARROWHEAD PHARMACEUTICALS, INC.\n\n  \n\nBy:/s/ Daniel Apel\n\n Daniel Apel\n\n Chief Financial Officer"}